<DOC>
	<DOCNO>NCT01735006</DOCNO>
	<brief_summary>This Phase III clinical trial novel recombinant HPV 16/18 bivalent vaccine manufacture Xiamen Innovax Biotech CO. , LTD . The primary objective study demonstrate efficacy vaccine relevant outcomes healthy woman 18 year old enrolment . The secondary objective evaluate safety , immunogenicity immuno-persistence vaccine . Meanwhile , study try compare difference safety immunogenicity among different lot . Approximately 6000 study subject enrol randomly stratify 2 group receive human papillomavirus ( HPV ) vaccine ( three different lot ) commercialize hepatitis E vaccine ( Hecolin ) accord 0-1-6 month schedule .</brief_summary>
	<brief_title>Efficacy Immunogenicity Study Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Female subject , include , 18 45 year age first vaccination ; 2 . Healthy subject establish medical history historyoriented clinical examination ; 3 . Be able understand comply request protocol ; 4 . Without acute cervicitis ; 5 . Not pregnant ; 6 . Have intact cervix . 1 . Use investigational nonregistered product ( drug vaccine ) within 30 day precede first vaccination , plan use study period ; 2 . Are use immunosuppressant ; 3 . Administration immunoglobulin and/or blood product within three month precede first vaccination plan administration study period ; 4 . Vaccinated inactivated vaccine 14 day attenuate vaccine 21 day enrollment ; 5 . Fever ; 6 . Concurrently participate another clinical trial ; 7 . Has receive vaccine HPV 16/18 ; 8 . Immunodeficient ; 9 . History allergic disease ; 10 . Serious medical disorder ; 11 . Blood coagulation disorder ; 12 . Epilepsy ; 13 . Unable comply protocol due mental illness ; 14 . Visible Condyloma ; 15 . Pregnant breastfeeding woman ; 16. vergins ; 17 . Have 4 sexual partner .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Human Papillomavirus 16</keyword>
	<keyword>Human Papillomavirus 18</keyword>
	<keyword>vaccine</keyword>
	<keyword>Cervical Intraepithelial Neoplasia</keyword>
	<keyword>cervical Cancer</keyword>
	<keyword>Vaginal intraepithelial neoplasia</keyword>
	<keyword>Vulvar intraepithelial neoplasia</keyword>
</DOC>